{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "AUD", "exchange": "ASX", "shortName": "NOXOPHARM FPO", "longName": "Noxopharm Limited", "messageBoardId": "finmb_346635783", "exchangeTimezoneName": "Australia/Sydney", "exchangeTimezoneShortName": "AEST", "gmtOffSetMilliseconds": 36000000, "market": "au_market", "esgPopulated": false, "regularMarketChangePercent": 9.302319, "regularMarketPrice": 0.047, "marketState": "POSTPOST", "fiftyTwoWeekHighChangePercent": -0.85538465, "fiftyTwoWeekLow": 0.041, "fiftyTwoWeekHigh": 0.325, "earningsTimestamp": 1682289513, "earningsTimestampStart": 1682289513, "earningsTimestampEnd": 1682289513, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.05, "sharesOutstanding": 292238016, "bookValue": 0.064, "fiftyDayAverage": 0.0803, "fiftyDayAverageChange": -0.033300005, "fiftyDayAverageChangePercent": -0.41469494, "twoHundredDayAverage": 0.1523625, "twoHundredDayAverageChange": -0.1053625, "twoHundredDayAverageChangePercent": -0.69152516, "marketCap": 13735186, "priceToBook": 0.73437494, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "tradeable": false, "cryptoTradeable": false, "priceHint": 4, "regularMarketChange": 0.003999997, "regularMarketTime": 1683871079, "regularMarketDayHigh": 0.048, "regularMarketDayRange": "0.043 - 0.048", "regularMarketDayLow": 0.043, "regularMarketVolume": 284295, "regularMarketPreviousClose": 0.043, "bid": 0.047, "ask": 0.048, "bidSize": 0, "askSize": 0, "fullExchangeName": "ASX", "financialCurrency": "AUD", "regularMarketOpen": 0.043, "averageDailyVolume3Month": 489053, "averageDailyVolume10Day": 843161, "fiftyTwoWeekLowChange": 0.0059999973, "fiftyTwoWeekLowChangePercent": 0.1463414, "fiftyTwoWeekRange": "0.041 - 0.325", "fiftyTwoWeekHighChange": -0.278, "firstTradeDateMilliseconds": 1470700800000, "symbol": "NOX.AX"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Tower A, The Zenith", "address2": "Level 20 821 Pacific Highway", "city": "Chatswood", "state": "NSW", "zip": "2067", "country": "Australia", "phone": "61 2 9144 2223", "fax": "61 2 9199 9600", "website": "https://www.noxopharm.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Gisela  Mautner", "title": "CEO, Exec. MD, Chief Medical Officer & Director", "fiscalYear": 2022, "totalPay": {"raw": 493666, "fmt": "493.67k", "longFmt": "493,666"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Shawn  Van Boheemen", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Jeanette  Bell Ph.D.", "title": "Chief Operating Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. John  Wilkinson B.Sc., Ph.D.", "title": "Chief Scientific Officer of Oncology", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Olivier  Laczka B.S., M.Sc., Ph.D.", "title": "Chief Scientific Officer of Inflammation", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP.", "age": 52, "title": "Company Sec.", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}